A Multicenter Phase 3, Open-Label, Randomized Study
177Lu-PNT2002 is a PSMA-targeted radioligand under investigation for the treatment of PSMA-avid metastatic castration-resistant prostate cancer (mCRPC).
Radiological progression-free survival (rPFS) assessed by Blinded Independent Central Review (BICR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (soft tissue) and Prostate Cancer Enrollment
415 Patients
*For complete inclusion and exclusion criteria, please visit clinicaltrials.gov and search for NCT04647526.